Global Immunotherapy Access

Global Immunotherapy Access

The Society for Immunotherapy of Cancer (SITC) welcomes scientists and clinicians throughout the world as we work to eradicate cancer using immunotherapies. SITC is working to break down the barriers to its educational programming and membership benefits by creating cost-effective opportunities for those who reside in low- and lower-middle income economies. These initiatives are spearheaded by the SITC Global Access and Impact Committee.

IT Starts With SITC Membership

SITC is the world’s leading member-driven society dedicated to professionals working in the field of cancer immunotherapy. It is SITC’s mission to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. 
 
As a SITC member, you will join a vibrant and growing global network of research scientists, physician scientists, clinicians, patients, patient advocates, government representatives and industry leaders. SITC offers complimentary membership for persons living in low- and lower-middle income countries. Once you become a SITC member and reside in a low- and lower-middle income country, SITC provides many educational programs at zero cost beginning in 2024.


LEARN:

Participate in low- or zero-cost educational programming

CONNECT:

Networking and volunteer opportunities to accelerate your career growth

PUBLISH:

Low-or zero-cost processing fees for articles accepted to the Journal for ImmunoTherapy of Cancer (JITC)

ENGAGE:

Numerous opportunities to showcase your research through funding, awards and abstracts

Immunotherapy Resources

39th Annual Meeting & Pre-Conference programs

As the largest conference focused solely on cancer immunotherapy, the SITC Annual Meeting & Pre-Conference Programs provides international leaders from academia, regulatory and government agencies, as well as industry representatives, with a multidisciplinary educational and interactive environment focused on improving outcomes for all cancer patients. Registration will be free for SITC members residing in low- and lower-middle income countries in 2024.

Learn More

Targets for Cancer IO: A Deep Dive Series

SITC is pleased to host its fourth Targets for Cancer IO: A Deep Dive Series. The series consists of highly focused webinars designed to dive deep into the science behind the most promising novel targets and pathways, from immune modulators to CD3 engagers and TCR by CD3 engagers in solid tumors, to role of neutrophils.

Explore the Series

Advances in Cancer Immunotherapy

Advances in Cancer Immunotherapy™

The Advances in Cancer Immunotherapy™ (ACI) educational series offers focused clinical education on a disease state or topic. Attendees of these half-day, innovative programs get in-depth training in immunotherapy treatment for a variety of topics from experts in the field. The ACI program also features discussions of closed cases submitted from attendees to hear guidance and insights from faculty. These programs are available at zero cost to the attendee.

LEARN MORE

SITC Cancer Immunotherapy Guidelines

Cancer immunotherapy clinical practice guidelines

The SITC Cancer Immunotherapy Guidelines program is a collection of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations on when and how to use immunotherapy to help improve outcomes for patients with cancer.

Discover CPGs

SITC Certificate in Cancer Immunotherapy

Certificate in Cancer Immunotherapy

The Certificate in Cancer Immunotherapy is offered online via the SITC connectED platform and consists of eight independent learning modules—all approved for CME, CNE, CPE and MOC credits—that can be stacked to earn the SITC Graduate in Cancer Immunotherapy (SITC-G) designation. The SITC-G designation identifies a healthcare provider as completing specialized training in cancer immunotherapy. The SITC-G designation certificate is available to those that are treating physicians (U.S. licensed MD / DO or global equivalent), or practicing licensed NP, PA, PharmD or RPh degree holders involved in direct clinical services, or global equivalent. For learners that do not meet the parameters above, a non-designation certificate track is available, for those who wish to further their immunology/immunotherapy education. Non-designation certificate learners are able to earn CME, CNE, CPE and MOC credit (as available in each module). Each module is available individually. This program is available at zero cost to members residing in low- and lower middle- income countries. 

Discover the Certificate in Cancer Immunotherapy

AI in IO: SITC-NCI Computational Immuno-oncology Webinar Series

In partnership with and partial funding by the National Cancer Institute (NCI), SITC is pleased to launch our fourth "SITC-NCI Computational Immuno-oncology Webinar Series" throughout May-December 2024. This year's series will focus specifically on the application of artificial intelligence (AI) in the field of immuno-oncology (IO). These nine free-to-attend digital events will help individual research labs to embrace the computational challenges of analyzing and integrating diverse assay data across the spectrum of immuno-oncology using AI.

Explore the Series

Cancer Immunotherapy winter school

Tailored to early-to-mid career scientists and clinicians in the field of cancer immunotherapy working in academic, clinical, industry and government settings, this hybrid program provides the best in cancer immunotherapy education taught by leading experts in the field.

Winter School participants gain a deep understanding of the core principles of tumor immunology and cancer immunotherapy, and developing areas in the field including biomarker technology, validation and clinical integration, clinical trial design, data analysis and considerations for combination therapies.

Learn More

Journal for ImmunoTherapy of Cancer

Journal for ImmunoTherapy of Cancer

The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application. 

JITC offers full waivers for the full Article Processing Charges (APC)–100% discount of the APC–where all authors are based in low-income countries. Requests for waivers must be made prior to submission.

Explore the Journal

Global Webinar series

This series focuses on the nuances of applying the latest scientific and clinical advances in cancer immunotherapy, discussing experiences of overcoming barriers while administering local immunotherapy treatment. 

Upcoming Events

If you are interested in learning more about upcoming SITC events and collaborative education programs, please visit the SITC event calendar.  



Global Access and Impact Committee

In 2018, the Society for Immunotherapy of Cancer (SITC) Board of Directors prioritized global access to cancer immunotherapy as a strategic goal for the society. To facilitate this goal, SITC formed the Global Access and Impact Committee. This committee, comprising an array of international stakeholders, seeks to develop strategies that overcome the challenges of science, education, policy and infrastructure within low- and lower-middle income economies to promote immunotherapy utilization and access across the world.